Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.
Authors
Angela Lamarca
Christie NHS Foundation Trust, Manchester, United Kingdom;
Angela Lamarca , Daniel H. Palmer , Harpreet Singh Wasan , Paul J. Ross , Yuk Ting Ma , Arvind Arora , Stephen Falk , Roopinder Gillmore , Jonathan Wadsley , Kinnari Patel , Alan Anthoney , Anthony Maraveyas , Claire Hobbs , Lorna Wilkinson , Timothy Macdonald , Claire Hartley , David Ryder , John A. Bridgewater , Juan W. Valle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01926236
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 593)
DOI
10.1200/JCO.2023.41.4_suppl.593
Abstract #
593
Poster Bd #
F5
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer.
First Author: Naminatsu Takahara
Poster
2016 Gastrointestinal Cancers Symposium
Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.
First Author: Maeve Aine Lowery
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2023 ASCO Annual Meeting
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
First Author: Samuel J Klempner